"The absence of any effect at one year is puzzling. It would have been reassuring to see at least a trend for benefit at one year, even if non-significant."

I rambled on this a bit in the post below. The was benefit at one year in both groups; however, only apabetalone group continued to improve. I hypothesize that it was a transient effect of these sickest patients getting into the clinic, receiving top standard of care and experiencing some benefit at one year regardless of apabetalone treatment. This standard of care effect was short-lived though and only apabetalone continued to shine beyond one year. Apabetalone had benefit both vs. baseline and placebo.

https://agoracom.com/ir/Resverlogix/forums/discussion/topics/734411-breakthrough-therapy-designation-application/messages/2251591#message

"And we still do not know whether eGFR improved, do we?"

Correct. Oh where, oh where is the CKD data? Oh where, oh where could it be? The company says all embargoes are done. Oh where, oh where is CKD?

https://twitter.com/BearDownAZ_2019/status/1202962714039128065?s=20